DIA 2013

49th Annual Meeting

Advancing Therapeutic Innovation and Regulatory Science

June 23-27, 2013 | Boston, MA | Event 13001 Boston Convention and Exhibition Center

Call for Professional Posters

Deadline: Thursday, February 28, 2013





Professional individuals from all fields related to the mission of the DIA are invited to submit a poster to be displayed at the DIA's 2013 49th Annual Meeting that will be held June 23-27 in Boston, MA. The Professional Poster Program is an opportunity for you to present your research to a diverse group of scientific professionals who are actively involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices, and health care related products. The theme of this year's Annual Meeting is "Advancing Therapeutic Innovation and Regulatory Science".


A maximum of 100 abstracts will be selected to participate in the Professional Poster Session that will be held on

Tuesday, June 25, 2013	11:45	AМ —	4:00	РМ
OR				
Wednesday, June 26, 2013	. 11:45	Ам —	4:00	РМ

Your session time will be assigned at the time of acceptance.

POSTER PRESENTERS WILL RECEIVE:

- Designated poster area and poster board area to display poster and network with attendees at the DIA Annual Meeting in Boston, MA
- Accepted abstracts will be posted on the DIA's 2013 49th Annual Meeting Website
- Electronic version of the poster to be displayed in the DIA's 2013 49th Annual Meeting Live Learning Center
- Abstract title and lead author will be printed in the final program that is distributed to Annual Meeting attendees



year! Of the D

ELIGIBILITY

- Individuals eligible to submit a professional poster include post-doctoral scholars, medical residents, fellows and professionals whose affiliation is consistent with the mission of DIA.
- Abstracts submitted for presentation must not have been presented or published previously.

GENERAL SUBMISSION REQUIREMENTS

(Please read the following instructions carefully, incorrect or incomplete abstracts will not be considered.)

- 1. All abstracts must be submitted online to **www.diahome.org**.
- 2. The title reflects the abstract content accurately and concisely.
- 3. All poster presentations must be noncommercial and scientific in nature and may not be used as a marketing opportunity. Any mention of specific products or and/or services must be limited to generic names, with no inclusion of brand names in any area of the poster, including poster titles and/or handouts. Logos and advertising may not appear anywhere on the poster.
- 4. Posters must be original in research and include appropriate empirical evidence.
- 5. Posters must include data, i.e., research results and conclusion for consideration.
- 6. Preliminary/pilot data is acceptable.

ONSITE REQUIREMENTS


- If an abstract is accepted, the primary author is required to pay
 the applicable meeting registration fee*, related expenses, and
 must be onsite at the DIA 2013 49th Annual Meeting in Boston
 during the designated poster session time.
 - Please note that an author may not represent more than one poster.
- Co-authors who would like to be present for your session must register by the deadline as well. If none of the authors are able to attend the meeting, your poster must be withdrawn from the program.
- Presenters must organize and pay for all shipping arrangements for their poster materials. DIA will not ship or store any materials.
- Presenters must prepare a poster to fit a 4'× 8' poster board (four feet high and eight feet wide).

Abstracts will be reviewed, and authors will be notified of results the week of March 18, 2013.

REQUIRED DOCUMENTATION FOR ALL ABSTRACTS

- Participant Disclosure Information all abstract authors must disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or providers of commercial services discussed in an educational presentation, as well as any discussion of unlabeled or unapproved drugs or devices. If you are proposing an abstract on behalf of the author, as the submitter you will not be asked to disclose. However, should the abstract be accepted, the author will be informed that he or she must respond to the Participant Disclosure to participate in the Annual Meeting Program.
- All submitters and authors must agree to the DIA Speaker Authorization for Use of Presentation Materials in order for the abstract to be a part of the *Annual Meeting* Program. Accepted posters will be available on the DIA's 2013 49th Annual Meeting website for attendee download.

DIA 2012 48TH ANNUAL MEETING ATTENDEE DEMOGRAPHICS BY PRODUCT RESPONSIBILITY



** Please plan on seeking company approval to provide an electronic copy of your poster before the deadline of June 6. Posters submitters are encouraged to submit topics related to one of the DIA 2013 49th Annual Meeting tracks noted below:

DIA 2013 49TH ANNUAL MEETING TRACKS

- Track 1: Clinical Operations
- Track 2 Project/Portfolio Management and Strategic Planning
- Track 3: Innovative Partnering Models and Outsourcing Strategies
- Track 4: Nonclinical and Translational Development/Early Phase Clinical Development
- Track 5: Regulation of Product Advertising and Marketing in an Ever-changing World
- Track 6: Medical Communications, Medical Writing and Medical Liaison
- Track 7: Processes and Technologies for Clinical Research
- Track 8: Regulatory Affairs and Submissions
- Track 9: Medical Devices, In Vitro Diagnostics, and Combination Products
- Track 10: Public Policy/Health Care Compliance/ Regulatory Law
- Track 11: Innovative Approaches to Ensuring Compliance with Good Clinical Practice, and Quality Assurance
- Track 12: Pharmaceutical Quality
- Track 13: Health Economics and Outcomes (HEO)/Comparative Effectiveness Research (CER)/Health Technology Assessment (HTA)
- Track 14: Clinical Safety and Pharmacovigilance
- Track 15: Statistical Science and Quantitative Thinking
- Track 16: Professional Development
- Track 17: Rare/Orphan Diseases

While the 2013 49th Annual Meeting Program Theme is "Advancing Therapeutic Innovation and Regulatory Science" the following are suggested hot topics for this year's Professional Poster Program:

- Neuroscience
- Oncology
- Cardiovascular/Metabolic
- Infectious Diseases
- Rare Diseases
- Women's Health
- Geriatrics
- Video Game Treatment for Therapeutic Intervention
- Vaccines and Biotech products
- Genomics and Personalized Medicine
- Interdisciplinary Clinical Research Activities
- Clinical Research, Regulatory and Site Operations
- Informatics and Biotechnology
- · Global Clinical Trials

SUBMITTED ABSTRACTS MUST INCLUDE THE FOLLOWING SECTIONS: The following information will be requested time of submission.

Author information The following information will need to be completed. Fields followed by an * are required. NOTE: If you are submitting on behalf of the author, you are considered the SUBMITTER and will need to complete the required information for yourself AND also for the AUTHOR. Submitters will be the contact for the author regarding the status of the abstract. If you are submitting your own abstract, you are considered the AUTHOR and will be the direct contact for this abstract.

Prefix:

First Name:*

Middle Name:

Last Name:* Name Suffix:

Degrees:

Job Title*:

Company*: Country*:

Address Line 1*:

City*:

State/Province*:

Zip/Postal Code*:

Phone*:

Email*:

Abstract Title* (125 characters including spaces) Titles should briefly describe the focus of the abstract as well as accurately reflect the content of the abstract.

REQUIRED FIELD (TO BE SUBMITTED ONLINE.)

Primary interest Area* (TRACK) Select the track in which your abstract should be included. There are 17 tracks that define the DIA 2013 49th Annual Meeting.

REQUIRED FIELD (TO BE SUBMITTED ONLINE.)

Keyword* (*Maximum* 100 characters including spaces) One or more key words are to be provided to highlight your abstract. Examples of key words: Personalized Medicine, Health Technology Assessment, Clinical Trial Agreements.

REQUIRED FIELD (TO BE SUBMITTED ONLINE.)

Objective* (Maximum 300 characters including spaces) Please provide a one sentence statement of the objective of the abstract.

REQUIRED FIELD (TO BE SUBMITTED ONLINE.)

Method* (Maximum 300 characters including spaces) When, where, and how was the study was done? What materials were used or who was included in the study?

REQUIRED FIELD (TO BE SUBMITTED ONLINE.)

Results* (*Maximum* 2000 characters including spaces) What quantitative data was collected; what answer was found to the research question; what did the study find? Was the tested hypothesis true?

REQUIRED FIELD (TO BE SUBMITTED ONLINE.)

Conclusion* (*Maximum* 2000 characters including spaces) State what can be concluded from the study and its implications.

Abstracts will be reviewed, and authors will be notified of results the week of March 18, 2013.

